BRPI1008035A2 - anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo - Google Patents

anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Info

Publication number
BRPI1008035A2
BRPI1008035A2 BRPI1008035A BRPI1008035A BRPI1008035A2 BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2 BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A BRPI1008035 A BR PI1008035A BR PI1008035 A2 BRPI1008035 A2 BR PI1008035A2
Authority
BR
Brazil
Prior art keywords
antibodies containing
therapeutic peptides
epo mimetic
containing tpo
mimetic therapeutic
Prior art date
Application number
BRPI1008035A
Other languages
English (en)
Inventor
Gies David
P Springhorn Jeremy
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BRPI1008035A2 publication Critical patent/BRPI1008035A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1008035A 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo BRPI1008035A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20848709P 2009-02-24 2009-02-24
PCT/US2010/024546 WO2010099019A1 (en) 2009-02-24 2010-02-18 Antibodies containing therapeutic tpo/epo mimetic peptides

Publications (1)

Publication Number Publication Date
BRPI1008035A2 true BRPI1008035A2 (pt) 2017-03-21

Family

ID=42665848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008035A BRPI1008035A2 (pt) 2009-02-24 2010-02-18 anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo

Country Status (14)

Country Link
US (1) US9493551B2 (pt)
EP (2) EP2401302A4 (pt)
JP (2) JP2012518408A (pt)
KR (1) KR20110122846A (pt)
CN (1) CN102428105B (pt)
AU (1) AU2010218277B2 (pt)
BR (1) BRPI1008035A2 (pt)
CA (1) CA2753438A1 (pt)
IL (1) IL214714A0 (pt)
MX (1) MX2011008936A (pt)
NZ (2) NZ603712A (pt)
RU (1) RU2559526C2 (pt)
SG (1) SG173680A1 (pt)
WO (1) WO2010099019A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192842A1 (en) * 2007-09-18 2010-06-09 Novozymes A/S Method for producing an acidified milk drink
WO2012121958A2 (en) * 2011-03-08 2012-09-13 Glaxosmithkline Llc Combination
WO2015024955A1 (en) * 2013-08-21 2015-02-26 Ureka Sarl Peptide-oligourea chimeric compounds and methods of their use
WO2016092922A1 (ja) * 2014-12-09 2016-06-16 電気化学工業株式会社 燃焼時の耐ドリップ性に優れたポリアミド系人工毛髪用繊維
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018222901A1 (en) * 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
BR112020001367A2 (pt) * 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
CA3127455A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
US11273203B2 (en) * 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
CN117986346A (zh) * 2024-04-07 2024-05-07 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
DE3852823T2 (de) 1987-09-11 1995-05-24 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
AU2323897A (en) 1996-03-29 1997-10-22 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
AU3117697A (en) 1996-05-06 1997-11-26 Uab Research Foundation, The Radiolabeled fusion toxins for cancer therapy
US7056897B2 (en) 1997-11-03 2006-06-06 The Arizona Board Of Regents Inducible expression vectors and methods of use thereof
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US7091396B1 (en) 2000-10-17 2006-08-15 The Rockefeller University Animals, cells and methods for production of detectably-labeled antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
DK1642910T3 (da) 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP1663278A4 (en) 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp EPO MIMETIC PEPTIDES AND FUSION PROTEINS
EP1687452A4 (en) * 2003-09-30 2008-08-06 Centocor Inc HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
ES2629397T3 (es) * 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
WO2007048022A2 (en) * 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia

Also Published As

Publication number Publication date
EP2401302A4 (en) 2013-10-09
JP2015043783A (ja) 2015-03-12
NZ594638A (en) 2013-03-28
EP2401302A1 (en) 2012-01-04
RU2559526C2 (ru) 2015-08-10
US9493551B2 (en) 2016-11-15
AU2010218277A1 (en) 2011-09-08
AU2010218277B2 (en) 2014-07-17
SG173680A1 (en) 2011-09-29
US20120070434A1 (en) 2012-03-22
CN102428105B (zh) 2015-09-30
KR20110122846A (ko) 2011-11-11
EP2752427A1 (en) 2014-07-09
RU2011139129A (ru) 2013-04-10
MX2011008936A (es) 2011-09-21
WO2010099019A1 (en) 2010-09-02
JP2012518408A (ja) 2012-08-16
CA2753438A1 (en) 2010-09-02
CN102428105A (zh) 2012-04-25
IL214714A0 (en) 2011-11-30
NZ603712A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
BRPI1008035A2 (pt) anticorpos contendo peptídeos terapêuticos miméticos de tpo/epo
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
BRPI1011005A2 (pt) anticorpos anti-epcam
EP2262831A4 (en) ANTI-properdin antibody
IL236236A (en) Antibodies to the fam26f polypeptide
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
BRPI0915718A2 (pt) peptídeos de direção crkl
BRPI0922716A2 (pt) purificação de polipeptídeo
GB0920981D0 (en) Peptides
GB0815788D0 (en) Therapeutic antibodies
IL212078A0 (en) Antibodies to modified human igf-1/e peptides
IL240134A0 (en) new proteins
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
IT1395137B1 (it) Nuovi peptidi antipatogeni
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2484694A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
GB0920987D0 (en) Peptides
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
GB0817978D0 (en) Peptides
EP2264057A4 (en) RECOMBINANT ANTIGEN
UA18028S (uk) Кришка до пляшки
GB0812093D0 (en) Phylloseptin peptides
GB0815673D0 (en) Peptides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]